

Pt no	Age /Sex	Arm	Status at infusion	EBV at Infusion	Donor	Cell dose	Transduction efficiency	% Lysis of SUPT1CD19/pt PHA blasts at 20:1	Average copy no
COHORT 1									
P000	8/M	Prophylactic	3 rd CR (MRD-ve) post 2 nd SCT	No	10/10 MUD	4 x 10 ⁷ /m ²	58.9%	50.1% / 1.1%	1.60
P002	9/F	Pre-emptive	Cytogenetic relapse post 1 st SCT	No	MSD	2 x 10 ⁸ /m ²	19.1%	71% / 0.6%	0.56
P004	12/M	Prophylactic	4 th molecular relapse post 1 st SCT*	No	MSD	2 x 10 ⁸ /m ²	32.8%	36.3% / 0.1%	0.56
P009	2/M	Pre-emptive	2 nd molecular relapse post 1 st SCT	No	10/10 MUD	2 x 10 ⁸ /m ²	34%	58.6% / 2%	0.85
P010	11/M	Prophylactic	3 rd molecular relapse post 2 nd SCT	Yes	MSD	4 x 10 ⁷ /m ²	26.9%	46.7% / 11.4%	0.43
P013	10/M	Prophylactic	3 rd CR (MRD-ve) post 2 nd SCT	No	10/10 MUD	2 x 10 ⁸ /m ²	25.3%	29.2% / 4.6%	0.32
COHORT 2									
P007	9/M	Pre-emptive	2 nd molecular relapse Post- 1 st SCT	No	MSD	2 x 10 ⁸ /m ²	32.8%	62.1% / 5%	0.31
P010	12/M	Prophylactic	4 th molecular relapse post-2 nd SCT	No	MSD	2 x 10 ⁸ /m ²	12%	53.6% / 9.6%	0.56
P019	8/F	Prophylactic	2 nd CR (MRD-ve) post 2 nd SCT	No	MSD	2 x 10 ⁸ /m ²	31%	52.7% / 2%	0.20
P022	11/M	Prophylactic	3 rd molecular relapse post 2 nd SCT	Yes	10/10 MUD	2 x 10 ⁸ /m ²	36%	34.9% / 1.1%	0.23
P025	9/M	Pre-emptive	2 nd molecular relapse post 1 st SCT	Yes	MSD	2 x 10 ⁸ /m ²	16.9%	54.4% / 1.5%	0.14
P027	6/M	Prophylactic	3 rd CR (MRD-ve) post 2 nd SCT	No	10/10 MUD	2 x 10 ⁸ /m ²	20.2%	60% / 2.9%	0.26

Table 1 – Patient Characteristics.

Patients in cohort 1 received CD19CAR CTL alone, those in cohort 2 received CD19CAR CTL with LCL vaccination. CR- complete remission; SCT- stem cell transplantation; MUD- matched unrelated donor; MSD- matched sibling donor, MRD- minimal residual disease. * P004 was recruited on to the prophylactic arm of the study but became unfit for second stem cell transplant and was withdrawn from the study. This patient was later treated off study without a second transplant